Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation
Cannabis Law Report
AUGUST 17, 2021
We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. percent, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial of 24.5 Chief Medical Officer of Marinus. “We Data Highlights.
Let's personalize your content